REAL-WORLD TREATMENT PATTERNS AND EFFICACY OF FIRST-LINE THERAPIES IN PATIENTS WITH MET EXON 14 SKIPPING-MUTATED NON-SMALL CELL LUNG CANCER
Author(s)
?. Z. ??, Haomin, Graduate student1, Li Xinyang, Graduate student2;
1Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China, China, 2School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China, China
1Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China, China, 2School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China, China
OBJECTIVES: Patients with non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping mutations face poor prognosis with standard therapies. This study aimed to analyze treatment patterns and evaluate the real-world efficacy of first-line treatments for advanced MET exon 14-mutated NSCLC.
METHODS: A retrospective analysis was conducted using electronic medical records from six tertiary hospitals in Jiangsu Province between January 2020 and December 2024. Efficacy was assessed per RECIST v1.1. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using the Kaplan-Meier method.
RESULTS: The study included 152 patients, predominantly elderly males (n=93) and never-smokers (n=114). Adenocarcinoma was the most common histology (n=119). First-line treatments included targeted therapy (n=91), chemotherapy (n=29), and combinations. For the entire cohort, the objective response rate (ORR) was 44.7% (95% CI: 36.7-53.0) and the disease control rate (DCR) was 64.5% (95% CI: 56.3-72.1). In the targeted therapy subgroup (n=91), the ORR and DCR were 60.4% (95% CI: 49.6-70.5) and 80.2% (95% CI: 70.6-87.8), respectively. With a median follow-up of 10.1 months, the median PFS for targeted therapy was 9.6 months (95% CI: 7.1-12.0).
CONCLUSIONS: Targeted therapy demonstrated superior real-world efficacy compared to other treatment modalities for MET exon 14-mutated NSCLC. These findings provide practical evidence for optimizing clinical treatment strategies for this patient population.
METHODS: A retrospective analysis was conducted using electronic medical records from six tertiary hospitals in Jiangsu Province between January 2020 and December 2024. Efficacy was assessed per RECIST v1.1. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using the Kaplan-Meier method.
RESULTS: The study included 152 patients, predominantly elderly males (n=93) and never-smokers (n=114). Adenocarcinoma was the most common histology (n=119). First-line treatments included targeted therapy (n=91), chemotherapy (n=29), and combinations. For the entire cohort, the objective response rate (ORR) was 44.7% (95% CI: 36.7-53.0) and the disease control rate (DCR) was 64.5% (95% CI: 56.3-72.1). In the targeted therapy subgroup (n=91), the ORR and DCR were 60.4% (95% CI: 49.6-70.5) and 80.2% (95% CI: 70.6-87.8), respectively. With a median follow-up of 10.1 months, the median PFS for targeted therapy was 9.6 months (95% CI: 7.1-12.0).
CONCLUSIONS: Targeted therapy demonstrated superior real-world efficacy compared to other treatment modalities for MET exon 14-mutated NSCLC. These findings provide practical evidence for optimizing clinical treatment strategies for this patient population.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
RWD119
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Oncology